Prospective Evaluation of Long-term Outcomes After Pulmonary Embolism (ELOPE)
The ELOPE Study: Prospective Evaluation of Long-term Outcomes After Pulmonary Embolism
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- QEII Health Sciences Centre
-
-
Ontario
-
Ottawa, Ontario, Canada, K1Y 4E9
- The Ottawa Hospital
-
Toronto, Ontario, Canada, M5G 2N2
- Toronto General Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Sir Mortimer B. Davis - Jewish General Hospital
-
Montreal, Quebec, Canada, H3T 1M5
- St. Mary's Hospital Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- First episode of acute symptomatic PE that was objectively diagnosed* within last 10 days
- Treated with anticoagulants
≥ 18 years old
- PE will be diagnosed if there is a high probability V/Q scan (as per PIOPED Study criteria 66), an intraluminal filling defect in segmental or larger vessels on CTPA or a constant intraluminal filling defect or abrupt cut-off of vessels greater than 2.5 mm diameter on pulmonary angiography 8,10. Patients with non-definitive test results (e.g. low or intermediate probability V/Q scan, subsegmental PE on CTPA (~5% of PE patients 12) will not be included in order to have a strictly defined population of patients with definite PE.
Exclusion Criteria:
- Contraindication or unable to perform CPET or 6MWT (amputated or paralyzed limb(s), severe lower extremity arthritis, preexisting cardiopulmonary condition precluding exercise including unstable angina or myocardial infarction in last 6 weeks, uncontrolled hypertension, serious cardiac dysrhythmia on resting EKG [severe bradycardia or tachycardia, sick sinus syndrome or multifocal premature ventricular contractions] and syncope)
- Contraindication to CTPA (allergy to iodinated contrast, CrCl or eGFR < 30 ml/min)
- Severe comorbidity (congestive heart failure [LVEF < 35%], severe COPD or restrictive lung disease [FEV1<50%, chronic need for oxygen therapy])
- Previous DVT (as ~40% of patients with proximal DVT have asymptomatic PE on lung imaging 67)
- Life expectancy < 1 year (e.g. active or terminal cancer, end-stage cardiac or respiratory disease).
- Pregnancy or lactation
- Unable to read questionnaire in English or French
- Unable to return to study centre for required follow-up visits
- Unable or unwilling to provide written informed consent
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Exercise Limitation
Time Frame: 1 month
|
Exercise limitation will be assessed by VO2 max (% predicted) on cardiopulmonary exercise testing (CPET)
|
1 month
|
|
Exercise Limitation
Time Frame: 12 months
|
Exercise limitation will be assessed by VO2 max (% predicted) on cardiopulmonary exercise testing (CPET)
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of Life
Time Frame: Baseline
|
Quality of Life will be assessed using the SF-36v2 questionnaire.
|
Baseline
|
|
Quality of Life
Time Frame: 1 month
|
Quality of Life will be assessed using the SF-36v2 questionnaire.
|
1 month
|
|
Quality of Life
Time Frame: 3 months
|
Quality of Life will be assessed using the SF-36v2 questionnaire.
|
3 months
|
|
Quality of Life
Time Frame: 6 months
|
Quality of Life will be assessed using the SF-36v2 questionnaire.
|
6 months
|
|
Quality of Life
Time Frame: 12 months
|
Quality of Life will be assessed using the SF-36v2 questionnaire.
|
12 months
|
|
Respiratory Disease-Specific Measures
Time Frame: Baseline
|
Respiratory Disease-Specific measures will be assessed using the Pulmonary Embolism Quality of Life Questionnaire (PEmb-QOL) and the San Diego Shortness of Breath Questionnaire (SOBQ).
|
Baseline
|
|
Respiratory Disease-Specific Measures
Time Frame: 1 month
|
Respiratory Disease-Specific measures will be assessed using the Pulmonary Embolism Quality of Life Questionnaire (PEmb-QOL) and the San Diego Shortness of Breath Questionnaire (SOBQ).
|
1 month
|
|
Respiratory Disease-Specific Measures
Time Frame: 3 months
|
Respiratory Disease-Specific measures will be assessed using the Pulmonary Embolism Quality of Life Questionnaire (PEmb-QOL) and the San Diego Shortness of Breath Questionnaire (SOBQ).
|
3 months
|
|
Respiratory Disease-Specific Measures
Time Frame: 6 months
|
Respiratory Disease-Specific measures will be assessed using the Pulmonary Embolism Quality of Life Questionnaire (PEmb-QOL) and the San Diego Shortness of Breath Questionnaire (SOBQ).
|
6 months
|
|
Respiratory Disease-Specific Measures
Time Frame: 12 months
|
Respiratory Disease-Specific measures will be assessed using the Pulmonary Embolism Quality of Life Questionnaire (PEmb-QOL) and the San Diego Shortness of Breath Questionnaire (SOBQ).
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Susan R Kahn, M.D., M.Sc., Sir Mortimer B. Davis - Jewish General Hospital
- Principal Investigator: Andrew Hirsch, M.D., Sir Mortimer B. Davis - Jewish General Hospital
- Principal Investigator: John Granton, M.D., University of Toronto
Publications and helpful links
General Publications
- Kahn SR, Hirsch AM, Akaberi A, Hernandez P, Anderson DR, Wells PS, Rodger MA, Solymoss S, Kovacs MJ, Rudski L, Shimony A, Dennie C, Rush C, Geerts WH, Aaron SD, Granton JT. Functional and Exercise Limitations After a First Episode of Pulmonary Embolism: Results of the ELOPE Prospective Cohort Study. Chest. 2017 May;151(5):1058-1068. doi: 10.1016/j.chest.2016.11.030. Epub 2016 Dec 6.
- Kahn SR, Houweling AH, Granton J, Rudski L, Dennie C, Hirsch A. Long-term outcomes after pulmonary embolism: current knowledge and future research. Blood Coagul Fibrinolysis. 2014 Jul;25(5):407-15. doi: 10.1097/MBC.0000000000000070.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MOP-93627
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.